There are no big surprises in Alzinova’s Q2’21 interim report.
Redeye comments on the Q2 report from Vicore. We provide a brief comment on the financials and highl...
Redeye maintains a positive view on LIDDS after today's Q2 report.
Redeye states that while semiconductor shortage affect automotive sales negatively, we maintain our ...
Q2 performance bodes well for FY guidance Revisions to reflect a change to calendar year Exciting ad...
Insplorions nettoomsättning Q2'21 var 0,5 mkr och EBITDA −3,5 mkr.
Omsättningen för Q2 uppgick till 2,8 mkr (2,8 mkr) motsvarande en organisk tillväxt om 1 %.
Intäkterna för Q2 var 36 mkr (31,5 mkr i Q2'20) motsvarande en tillväxt om 14 %.
Nettoomsättningen steg 38% y/y till 3,5 mkr (2,5), vilket var något under vår förväntan om 5,0 mkr.
Sales and profits in Q2 were lower than our estimates.
Redeye briefly comments on Cereno’s Q2 2021 report, which came without any surprises.
DistIT AB (publ) (”DistIT” eller ”Bolaget”) är historiskt ett distributionsbolag som nu är i början ...
Redeye provides a brief comment on Clavister's Q2 report.
FluoGuide has been demonstrating good progress with its clinical and preclinical programs, and FG001 appears to be exceeding expectations, w...
Footway Group – the online footwear and sports retailer – reported Q2 sales and earnings below our e...
While Q2 sales came in ahead of our estimates, adjusted EBITA was SEK 14m lower than expected, mainl...
AcouSort publicerade den 25 augusti 2021 sin delårsrapport för årets andra kvartal.
Duearity publicerade idag den 25 augusti sin delårsrapport för årets andra kvartal.
Redeye gives its first impression on Alzecure’s Q2’21 report.
BuildData Group (previously Zutec) reports Q4 20/21 on 13 September.
Plexian publicerade idag den 25 augusti sin delårsrapport för årets andra kvartal.
Rörelsekostnaderna i Q2 ökade jämfört med samma period i fjol till 7,5 mkr (2,9).
Redeye’s points to more robust potential partner support for CHS coated medical devices.
Newton Nordic publicerade idag den 25 augusti 2021 sin delårsrapport för andra kvartalet 2021.
Redeye notes that the Q2 report came in below our estimates on both sales and EBIT.
Redeye sees Paynova taking the proper steps forward with its BNPL solution with Viggoshop and going ...
Redeye leaves its view on InDex Pharmaceuticals following the announcement of its Q2 report.
